BAX and colorectal carcinoma: The Bcl-xL overexpression is often correlated with cancer aggressiveness and chemoresistance to therapeutics, which is negatively controlled by Bax. The overexpression of Bcl-2 family has been detected in about 30–94% of human CRC (23, 27).